// App-Quantinova.ai

: Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer.

Researchers

Presenter

  • Michal Sarfaty

Principal Investigators

  • Peter Hall

  • Kelvin K. Chan

  • Kiran Virik

  • Moshe Leshno

  • Noa Gordon

  • Assaf Moore

  • Victoria Neiman

  • Eli Rosenbaum

  • Daniel A. Goldstein

Medical Centers

  • Davidoff Cancer Center, Petach Tiqwa, Israel

  • Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom

  • Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Queen's University/Cancer Centre of SE Ontario, Kingston, ON, Canada

  • Coller School of Management, Tel Aviv University, Tel Aviv, Israel

  • Davidoff Cancer Center, Petach Tiqwa, Israel

  • Davidoff Center, Rabin Medical Center, Petach-Tikva, Israel

Locations

  • Israel

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved